Key facts
- Accure for Acne’s last known valuation is $67.4M (Jan 2022).
- It has raised $60.8M; the latest was Later Stage VC ($24.1M) in Nov 2025.
- Notable investors include Ms2 Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Accure for Acne
- ·The full record, as it builds
Funding rounds
No funding rounds for Accure for Acne are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accure for Acne
Developer of a laser technology designed to reduce or prevent the recurrence of acne vulgaris. The company's laser technology selectively damages overactive sebaceous glands through selective photothermolysis while sparing the surrounding epidermis from damage, enabling acne patients to minimize the recurrence of inflammatory acne lesions in the treated areas.
- Sector
- Healthcare
- HQ
- Boulder, CO, United States
- Founded
- 2015
- Employees
- 22
- Website
- accureacne.com/
- Ownership
- Privately Held (backing)
Accure for Acne doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accure for Acne shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accure for Acne in its N-PORT filings yet. We sweep new filings monthly.